SG10201600836PA - Synthetic mimics of mir-34 - Google Patents

Synthetic mimics of mir-34

Info

Publication number
SG10201600836PA
SG10201600836PA SG10201600836PA SG10201600836PA SG10201600836PA SG 10201600836P A SG10201600836P A SG 10201600836PA SG 10201600836P A SG10201600836P A SG 10201600836PA SG 10201600836P A SG10201600836P A SG 10201600836PA SG 10201600836P A SG10201600836P A SG 10201600836PA
Authority
SG
Singapore
Prior art keywords
mir
synthetic mimics
mimics
synthetic
Prior art date
Application number
SG10201600836PA
Other languages
English (en)
Inventor
Kevin Kelnar
David Brown
Original Assignee
Mirna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirna Therapeutics Inc filed Critical Mirna Therapeutics Inc
Publication of SG10201600836PA publication Critical patent/SG10201600836PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
SG10201600836PA 2011-02-03 2012-02-03 Synthetic mimics of mir-34 SG10201600836PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161439280P 2011-02-03 2011-02-03

Publications (1)

Publication Number Publication Date
SG10201600836PA true SG10201600836PA (en) 2016-03-30

Family

ID=45592829

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013058466A SG192252A1 (en) 2011-02-03 2012-02-03 Synthetic mimics of mir-34
SG10201600836PA SG10201600836PA (en) 2011-02-03 2012-02-03 Synthetic mimics of mir-34

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013058466A SG192252A1 (en) 2011-02-03 2012-02-03 Synthetic mimics of mir-34

Country Status (16)

Country Link
US (3) US8586727B2 (zh)
EP (2) EP3178932A1 (zh)
JP (2) JP2014506791A (zh)
KR (1) KR20140020900A (zh)
CN (1) CN103476931A (zh)
AU (1) AU2012212023B9 (zh)
BR (1) BR112013019853A2 (zh)
CA (1) CA2825981A1 (zh)
CL (1) CL2013002195A1 (zh)
IL (1) IL227697A0 (zh)
MX (1) MX342927B (zh)
MY (1) MY165507A (zh)
RU (1) RU2615117C2 (zh)
SG (2) SG192252A1 (zh)
WO (1) WO2012106591A1 (zh)
ZA (1) ZA201306518B (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006137941A2 (en) 2004-11-12 2006-12-28 Ambion, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
EP2990487A1 (en) 2008-05-08 2016-03-02 Asuragen, INC. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
US8846631B2 (en) 2010-01-14 2014-09-30 Regulus Therapeutics Inc. MicroRNA compositions and methods
WO2012041959A1 (en) 2010-09-30 2012-04-05 University Of Zurich Treatment of b-cell lymphoma with microrna
CN103459598B (zh) 2011-02-03 2016-08-10 米尔纳医疗股份有限公司 Mir-124的合成模拟物
SG192252A1 (en) 2011-02-03 2013-09-30 Mirna Therapeutics Inc Synthetic mimics of mir-34
MX359548B (es) * 2011-11-18 2018-10-02 Alnylam Pharmaceuticals Inc Agentes de iarn modificados.
CN109810977A (zh) 2012-05-26 2019-05-28 株式会社博纳克 具有递送功能的基因表达调控用单链核酸分子
US20140308274A1 (en) * 2013-03-15 2014-10-16 Mirna Therapeutics, Inc. Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors
AU2014228166A1 (en) * 2013-03-15 2015-09-24 Mirna Therapeutics, Inc. Combination cancer treatments utilizing micrornas and EGFR-TKI inhibitors
JP2016530232A (ja) 2013-06-24 2016-09-29 ミルナ セラピューティクス，インク． Ｍｉｒ−３４活性のバイオマーカー
EP3088524A4 (en) 2013-12-26 2017-08-09 Tokyo Medical University Artificial mimic mirna for controlling gene expression, and use of same
WO2015099188A1 (ja) * 2013-12-27 2015-07-02 株式会社ボナック 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
SG11201605247XA (en) 2013-12-27 2016-08-30 Bonac Corp Artificial match-type mirna for controlling gene expression and use therefor
GB201400598D0 (en) 2014-01-14 2014-03-05 Univ Glasgow Materials and methods for modulation of tendon healing
EP3126496A1 (en) 2014-04-01 2017-02-08 Mirna Therapeutics, Inc. Microrna dosing regimens
KR101811731B1 (ko) * 2014-07-29 2018-01-25 재단법인 아산사회복지재단 Met 저해제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
WO2016081773A2 (en) * 2014-11-19 2016-05-26 Mirna Therapeutics, Inc. Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides
CN107109415B (zh) * 2014-12-27 2021-07-09 株式会社博纳克 控制基因表达的天然型miRNA及其用途
WO2016158809A1 (ja) 2015-03-27 2016-10-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
EP3426781B1 (en) 2016-03-07 2024-06-26 The United States of America, as represented by The Secretary, Department of Health and Human Services Micrornas and methods of their use
EP3216869B1 (en) 2016-03-09 2019-09-18 Colizzi, Vittorio Nutraceutical plant derived microrna elements for treatment of leukemia
CN105779452A (zh) * 2016-03-10 2016-07-20 上海吉玛制药技术有限公司 一种抑制肿瘤生长的寡聚核酸及其应用
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC EXOSOMES FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
CN107699565B (zh) * 2017-11-24 2020-05-22 苏州大学 微小rna及其在制备抗肿瘤药物中的应用
EP3626820A1 (en) * 2018-09-20 2020-03-25 Fundación Imdea Nanociencia Anticancer compositions containing mirna mimics and uses thereof
AU2021246530A1 (en) 2020-04-02 2022-11-03 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US5583013A (en) 1977-11-08 1996-12-10 Genentech, Inc. Method and means for microbial polypeptide expression
US5221619A (en) 1977-11-08 1993-06-22 Genentech, Inc. Method and means for microbial polypeptide expression
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4682195A (en) 1985-09-30 1987-07-21 General Electric Company Insulated gate device with configured emitter contact pad
US4959463A (en) 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4667013A (en) 1986-05-02 1987-05-19 Union Carbide Corporation Process for alkylene oxide polymerization
EP0266032A1 (en) 1986-08-29 1988-05-04 Beecham Group Plc Modified fibrinolytic enzyme
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4816571A (en) 1987-06-04 1989-03-28 Applied Biosystems, Inc. Chemical capping by phosphitylation during oligonucleotide synthesis
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5602244A (en) 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5141813A (en) 1989-08-28 1992-08-25 Clontech Laboratories, Inc. Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
DK0497875T3 (da) 1989-10-24 2000-07-03 Gilead Sciences Inc 2'-modificerede oligonukleotider
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
DE69032425T2 (de) 1990-05-11 1998-11-26 Microprobe Corp., Bothell, Wash. Teststreifen zum Eintauchen für Nukleinsäure-Hybridisierungsassays und Verfahren zur kovalenten Immobilisierung von Oligonucleotiden
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
EP0538194B1 (de) 1991-10-17 1997-06-04 Novartis AG Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
DE4204650C1 (zh) 1992-02-15 1993-07-08 Hoffmeister, Helmut, Dr., 4400 Muenster, De
US5428148A (en) 1992-04-24 1995-06-27 Beckman Instruments, Inc. N4 - acylated cytidinyl compounds useful in oligonucleotide synthesis
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
EP0691968B1 (en) 1993-03-30 1997-07-16 Sanofi Acyclic nucleoside analogs and oligonucleotide sequences containing them
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5574146A (en) 1994-08-30 1996-11-12 Beckman Instruments, Inc. Oligonucleotide synthesis with substituted aryl carboxylic acids as activators
US5554744A (en) 1994-09-23 1996-09-10 Hybridon, Inc. Method for loading solid supports for nucleic acid synthesis
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5705629A (en) 1995-10-20 1998-01-06 Hybridon, Inc. Methods for H-phosphonate synthesis of mono- and oligonucleotides
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5846225A (en) 1997-02-19 1998-12-08 Cornell Research Foundation, Inc. Gene transfer therapy delivery device and method
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
KR100517163B1 (ko) * 2000-02-10 2005-09-26 미쯔이카가쿠 가부시기가이샤 1-인산화 당유도체 아노머의 선택적인 제조방법 및뉴클레오사이드의 제조방법
WO2003029459A2 (en) 2001-09-28 2003-04-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Micro-rna molecules
WO2003093441A2 (en) 2002-05-03 2003-11-13 Duke University A method of regulating gene expression
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
CN1768139A (zh) 2003-02-10 2006-05-03 独立行政法人产业技术总合研究所 通过dna干扰调控基因的表达
US20050059024A1 (en) 2003-07-25 2005-03-17 Ambion, Inc. Methods and compositions for isolating small RNA molecules
EP1648914A4 (en) 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
EP2295604B1 (en) 2004-02-09 2015-04-08 Thomas Jefferson University Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
AU2005214904B2 (en) 2004-02-13 2011-07-21 Rockefeller University Anti-microRNA oligonucleotide molecules
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
US7365058B2 (en) 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
EP2290071B1 (en) 2004-05-28 2014-12-31 Asuragen, Inc. Methods and compositions involving microRNA
WO2006137941A2 (en) 2004-11-12 2006-12-28 Ambion, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
US7074622B2 (en) 2004-11-15 2006-07-11 Eastman Kodak Company Method and system for sorting and separating particles
ES2545119T3 (es) 2006-01-05 2015-09-08 The Ohio State University Research Foundation Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos
AU2007333109A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro RNAs
JP5145557B2 (ja) * 2007-03-01 2013-02-20 財団法人ヒューマンサイエンス振興財団 マイクロｒｎａを有効成分として含有する腫瘍増殖抑制剤、および癌治療用医薬組成物
PL2147122T3 (pl) * 2007-04-20 2015-05-29 Leadiant Biosciences Ltd Enzymatyczna terapia przeciwnowotworowa
EP2152722B1 (en) 2007-05-03 2016-04-27 Merck Sharp & Dohme Corp. Compositions comprising mir34 therapeutic agents for treating cancer
CA2689974A1 (en) 2007-06-08 2008-12-18 Asuragen, Inc. Mir-34 regulated genes and pathways as targets for therapeutic intervention
WO2009058907A2 (en) 2007-10-29 2009-05-07 Isis Pharmaceuticals, Inc. Targeting micrornas for the treatment of liver cancer
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2010056737A2 (en) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells
JP2010268690A (ja) * 2009-05-19 2010-12-02 Nippon Kayaku Co Ltd 抗腫瘍活性を持つ化合物の感受性の判定方法
SG192252A1 (en) 2011-02-03 2013-09-30 Mirna Therapeutics Inc Synthetic mimics of mir-34
CN103459598B (zh) 2011-02-03 2016-08-10 米尔纳医疗股份有限公司 Mir-124的合成模拟物
CN103186763B (zh) 2011-12-28 2017-07-21 富泰华工业（深圳）有限公司 人脸识别***及方法

Also Published As

Publication number Publication date
BR112013019853A2 (pt) 2017-03-21
MX2013008945A (es) 2014-01-08
EP2670850A1 (en) 2013-12-11
US8586727B2 (en) 2013-11-19
EP2670850B1 (en) 2016-10-26
RU2013140634A (ru) 2015-03-10
WO2012106591A1 (en) 2012-08-09
MY165507A (en) 2018-03-28
SG192252A1 (en) 2013-09-30
US20140107182A1 (en) 2014-04-17
RU2615117C2 (ru) 2017-04-04
CL2013002195A1 (es) 2014-05-30
EP3178932A1 (en) 2017-06-14
IL227697A0 (en) 2013-09-30
ZA201306518B (en) 2014-05-28
CA2825981A1 (en) 2012-08-09
JP2016152804A (ja) 2016-08-25
MX342927B (es) 2016-10-19
AU2012212023A1 (en) 2013-09-12
KR20140020900A (ko) 2014-02-19
US20160053264A1 (en) 2016-02-25
JP2014506791A (ja) 2014-03-20
US9371526B2 (en) 2016-06-21
CN103476931A (zh) 2013-12-25
AU2012212023B9 (en) 2017-01-12
US20120288933A1 (en) 2012-11-15
AU2012212023B2 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
ZA201306518B (en) Synthetic mimics of mir-34
HK1245491A1 (zh) 計算機可讀介質
EP2717099A4 (en) TONER
EP2717100A4 (en) TONER
EP2710430A4 (en) INK POWDER
EP2710432A4 (en) TONER
EP2691815A4 (en) TONER
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
EP2710431A4 (en) TONER
ZA201307806B (en) Synthetic genes
GB2503849B (en) Intrinsically-calibrated tribometer
EP2753839A4 (en) decoupler
EP2729605A4 (en) RNA YY1 INTERACTIONS
PL395178A1 (pl) Endorybonukleazy dsRNA
SG11201403280PA (en) Bioreactor
EP2753982A4 (en) TONER
GB201410312D0 (en) Photobioreactor
GB2532391B (en) Diaphragm
EP2705283A4 (en) DIAPHRAGM
HK1199040A1 (zh) 抗體用途
GB201119167D0 (en) Novel bachteriophages
EP2768941A4 (en) photobioreactor
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
GB2497504B (en) Amphibian